Significance of survivin expression: Prognostic value and survival in stage III non-small cell lung cancer

Wang,Meng; Liu,Bao-Gang; Yang,Zhao-Yang; Hong,Xuan; Chen,Gong-Yan

doi:10.3892/etm.2012.512

Significance of survivin expression: Prognostic value and survival in stage III non-small cell lung cancer

Authors:
- Meng Wang
- Bao-Gang Liu
- Zhao-Yang Yang
- Xuan Hong
- Gong-Yan Chen
View Affiliations

Affiliations: Department of Respiratory Medicine, The Third Affiliated Hospital of Harbin Medical University, Harbin 150086, P.R. China
Published online on: March 12, 2012 https://doi.org/10.3892/etm.2012.512
Pages: 983-988

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study was designed to determine the levels of survivin expression and identify its clinical significance as a prognostic factor for stage III non-small cell lung cancer (NSCLC). A total of 210 cases of stage III NSCLC were collected and the expression levels of survivin and vascular endothelial growth factor A (VEGF-A) in tumor tissues were investigated using immunohistochemistry (IHC). The medical records of the patients were reviewed to determine the association with clinical course. Of the 210 NSCLC tissues, 112 (53.3%) cases demonstrated positive expression of survivin protein. Coexpression of survivin and VEGF-A was identified. The 5-year survival rate of patients with positive survivin expression was significantly lower compared with the survivin-negative cancer patients (P<0.05). The expression of survivin in NSCLC correlated with tumor size. Survivin and VEGF-A were independent prognostic factors of stage III NSCLC. Survivin protein is a valuable marker of prognosis in stage III NSCLC patients.

View Figures

View References

1.	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics. CA Cancer J Clin. 59:225–249. 2009.
2.	Srinivasula SM and Ashwell JD: IAPs: what's in a name? Mol Cell. 30:123–135. 2008.
3.	Hernandez JM, Farma JM, Coppola D, Hakam A, Fulp WJ, Chen DT, Siegel EM, Yeatman TJ and Shibata D: Expression of the antiapoptotic protein survivin in colon cancer. Clin Colorectal Cancer. 10:188–193. 2011. View Article : Google Scholar : PubMed/NCBI
4.	Pavlyukov MS, Antipova NV, Balashova MV, Vinogradova TV, Kopantzev EP and Shakhparonov MI: Survivin monomer plays an essential role in apoptosis regulation. J Biol Chem. 286:23296–23307. 2011. View Article : Google Scholar : PubMed/NCBI
5.	Nowak-Markwitz E, Puła B, Szajnik M, Dziegiel P, Piotrowska A, Zabel M and Spaczyński M: Expression of survivin, SDF-1 and CXCR on tumor cells in ovarian cancer. Ginekol Pol. 81:674–677. 2010.PubMed/NCBI
6.	Kim K, Chie EK, Wu HG, Kim SG, Lee SH, Kang GH, Hyun CL and Ha SW: High survivin expression as a predictor of poor response to preoperative chemoradiotherapy in locally advanced rectal cancer. Int J Colorectal Dis. 26:1019–1023. 2011. View Article : Google Scholar : PubMed/NCBI
7.	Adamkov M, Halasova E, Kajo K, Machalekova K, Vybohova D, Varga I and Rajcany J: Survivin: a promising biomarker in breast carcinoma. Neoplasma. 57:572–577. 2010. View Article : Google Scholar : PubMed/NCBI
8.	Hoffman WH, Biade S, Zilfou JT, Chen J and Murphy M: Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem. 277:3247–3257. 2002. View Article : Google Scholar : PubMed/NCBI
9.	Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, Nielsen LL, Pickett CB and Liu S: Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene. 21:2613–2622. 2002. View Article : Google Scholar : PubMed/NCBI
10.	Lee CW, Raskett CM, Prudovsky I and Altieri DC: Molecular dependence of estrogen receptor-negative breast cancer on a notch-survivin signaling axis. Cancer Res. 68:5273–5281. 2008. View Article : Google Scholar : PubMed/NCBI
11.	Vaira V, Lee CW, Goel HL, Bosari S, Languino LR and Altieri DC: Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene. 26:2678–2684. 2007. View Article : Google Scholar : PubMed/NCBI
12.	Li F: Survivin study: what is the next wave? J Cell Physiol. 197:8–29. 2003. View Article : Google Scholar : PubMed/NCBI
13.	Altieri DC, Marchisio PC and Marchisio C: Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest. 79:1327–1333. 1999.PubMed/NCBI
14.	Shu MG, Guo XT, Zhen HN, Han Y, Chen FL, Li LW and Guo SZ: Enhancing skin flap survival by a cell-permeable wild-type survivin. Med Hypotheses. 69:888–891. 2007. View Article : Google Scholar : PubMed/NCBI
15.	Zhu H, Wang Q, Hu C, Zhang W, Quan L, Liu M, Xu N and Xiao Z: High expression of survivin predicts poor prognosis in esophageal squamous cell carcinoma following radiotherapy. Tumour Biol. 32:1147–1153. 2011. View Article : Google Scholar : PubMed/NCBI
16.	Trabulo S, Cardoso AM, Santos-Ferreira T, Cardoso AL, Simões S and Pedroso de Lima MC: Survivin silencing as a promising strategy to enhance the sensitivity of cancer cells to chemotherapeutic agents. Mol Pharm. 8:1120–1131. 2011. View Article : Google Scholar : PubMed/NCBI
17.	Park E, Gang EJ, Hsieh YT, Schaefer P, Chae S, Klemm L, Huantes S, Loh M, Conway EM, Kang ES, Hoe Koo H, Hofmann WK, Heisterkamp N, Pelus L, Keerthivasan G, Crispino J, Kahn M, Müschen M and Kim YM: Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. Blood. 118:2191–2199. 2011. View Article : Google Scholar : PubMed/NCBI
18.	Takizawa BT, Uchio EM, Cohen JJ, Wheeler MA and Weiss RM: Downregulation of survivin is associated with reductions in TNF receptors' mRNA and protein and alterations in nuclear factor kappa B signaling in urothelial cancer cells. Cancer Invest. 25:678–684. 2007.PubMed/NCBI
19.	Ai Z, Yin L, Zhou X, Zhu Y, Zhu D, Yu Y and Feng Y: Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer. Cancer. 107:746–756. 2006. View Article : Google Scholar : PubMed/NCBI
20.	Malcles MH, Wang HW, Koumi A, Tsai YH, Yu M, Godfrey A and Boshoff C: Characterisation of the anti-apoptotic function of survivin-DeltaEx3 during TNF alpha-mediated cell death. Br J Cancer. 96:1659–1666. 2007. View Article : Google Scholar : PubMed/NCBI
21.	Nassar A, Lawson D, Cotsonis G and Cohen C: Survivin and caspase-3 expression in breast cancer: correlation with prognostic parameters, proliferation, angiogenesis, and outcome. Appl Immunohistochem Mol Morphol. 16:113–120. 2008. View Article : Google Scholar : PubMed/NCBI
22.	Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med. 9:669–676. 2003. View Article : Google Scholar : PubMed/NCBI
23.	Giatromanolaki A, Sivridis E and Koukourakis MI: Angiogenesis in colorectal cancer: prognostic and therapeutic implications. Am J Clin Oncol. 29:408–417. 2006. View Article : Google Scholar : PubMed/NCBI
24.	Kleespies A: Vascular endothelial growth factor in esophageal cancer. J Surg Oncol. 87:95–104. 2004. View Article : Google Scholar : PubMed/NCBI
25.	Yasumitsu A, Tabata C, Tabata R and Hirayama N: Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thorac Oncol. 5:479–483. 2010. View Article : Google Scholar : PubMed/NCBI
26.	Zhu H, Chen XP, Zhang WG, Luo SF and Zhang BX: Expression and significance of new inhibitor of apoptosis protein survivin in hepatocellular carcinoma. World J Gastroenterol. 11:3855–3859. 2005.PubMed/NCBI
27.	Zhang HY, Meng X, Du ZX, et al: Significance of survivin, caspase-3, and VEGF expression in thyroid carcinoma. Clin Exp Med. 9:207–213. 2009. View Article : Google Scholar : PubMed/NCBI
28.	Ryan BM, Konecny GE, Kahlert S, Wang HJ, Untch M, Meng G, Pegram MD, Podratz KC, Crown J, Slamon DJ and Duffy MJ: Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol. 17:597–604. 2006. View Article : Google Scholar : PubMed/NCBI
29.	Beierle EA, Nagaram A, Dai W, Iyengar M and Chen MK: VEGF-mediated survivin expression in neuroblastoma cells. J Surg Res. 127:21–28. 2005. View Article : Google Scholar : PubMed/NCBI
30.	Nakahara T, Yamanaka K, Hatakeyama S, Kita A, Takeuchi M, Kinoyama I, Matsuhisa A, Nakano K, Shishido T, Koutoku H and Sasamata M: YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model. Anticancer Drugs. 22:454–462. 2011. View Article : Google Scholar : PubMed/NCBI